Machens A, Bensch C, Wickenhauser C, Dralle H, Lorenz K. Forgoing Node Dissection for Desmoplasia-Negative Hereditary Medullary Thyroid Cancer. Endocr Relat Cancer. 2026 Aug 10:ERC-26-0148. doi: 10.1530/ERC-26-0148. Epub ahead of print. PMID: 42573140.
Ceran E, Jaramillo Segura S, Merbach AK, Rohde C, Wass M, Schaffrath J, Durruthy-Durruthy R, Arribas-Layton M, Sciambi A, Rieger K, Nogai A, Hänel M, Herbst R, Stölzel F, Röllig C, Jost E, Schlenk RF, Lotze M, Noppeney R, Brandts C, Krug U, Götze KS, Buske S, Florschütz A, Schubert J, Opitz B, Eßeling E, von Witzendorff S, Subklewe M, Kaufmann M, Frickhofen N, Scholz CW, Schäfer-Eckart K, Kunzmann V, Schmidt-Hieber M, Sayer H, Rank A, Hemmati P, Schüler F, Scheller M, Kowoll S, Steighardt J, Edemir B, Ludwig-Kraus B, Müller LP, Edemir S, Vainstein-Haras A, Sorani E, Glicko-Kabir I, Kadosh S, Tavor S, Gromann C, Wienke A, Bauer M, Wickenhauser C, Baldus CD, Platzbecker U, Cerwenka A, Serve H, Bornhäuser M, Junghanß C, Müller-Tidow C. Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation. Blood. 2026 Jul 30;148(5):545-559. doi: 10.1182/blood.2025032033. PMID: 41980027.
Wickenhauser C, Fend F. Molekulare Pathologie als Innovationstreiber und Garant einer optimierten onkologischen Versorgung. Pathologie (Heidelb). 2026 Jul;47(4):237-238. German. doi: 10.1007/s00292-026-01573-8. Epub 2026 Jun 26. PMID: 42360475.
Seliger B. "Tumor Immunology Meets Oncology" (TIMO), 22 May-24 May 2025 in Brandenburg an der Havel, Germany. Cancer Immunol Immunother. 2026 Jun 23;75(7):172. doi: 10.1007/s00262-026-04468-y. PMID: 42337059; PMCID: PMC13315368.
Heuser M, Wickenhauser C, Oevel L, Bauer M. Leitlinienentwicklung zur MRD-Diagnostik der AML als Blaupause für solide Tumoren [Guideline development for MRD diagnostics in AML as a blueprint for solid tumors]. Pathologie (Heidelb). 2026 Jul;47(4):273-281. German. doi: 10.1007/s00292-026-01576-5. Epub 2026 Jun 22. PMID: 42329370.
Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Bauer M, Wickenhauser C, Schiefer D, Hilger N, Blaudszun AR, Thees J, Walter J, Tretbar US, Koehl U, Fricke S, Blache U. Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation. Blood. 2026 May 14;147(20):2402-2414. doi: 10.1182/blood.2025031370. PMID: 41587074; PMCID: PMC13197980.
Seliger B, Mantke R, Naß N, Dammermann W, Ocvirk S, Kah J, Kalinski T, Massa C. Inflammation and Colorectal Cancer Pathogenesis: Molecular, Immunological, and Environmental Features for Therapy Response and Resistances. Int J Mol Sci. 2026 May 12;27(10):4299. doi: 10.3390/ijms27104299. PMID: 42196281; PMCID: PMC13206906.
Blümke J, Seliger B. Interferon lambda in anti-viral defense and cancer: dual roles, mechanism and therapeutic potential. J Transl Med. 2026 May 6;24(1):830. doi: 10.1186/s12967-026-08209-8. PMID: 42092929; PMCID: PMC13317279.
Melief J, Baldran-Groves L, Gerault MA, Liang YY, Pasca S, de Los Santos MC, Wickström S, Lövgren T, Ramos AD, Larsson LG, Nordlund P, Seliger B, Kiessling R. Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8+ T cells. Oncoimmunology. 2026 Dec 31;15(1):2658916. doi: 10.1080/2162402X.2026.2658916. Epub 2026 Apr 29. PMID: 42057381; PMCID: PMC13134409.
Trost F, Zhang B, Aring I, Bauer M, Glamann L, Wessolly M, Johnson K, Göbel H, Lerbs T, Sangenne T, Herrmann P, Mairinger F, Kopp C, Michels S, Rasokat A, Heldwein M, Wagner S, Schömig-Markiefka B, Wolf J, Hartmann S, Wickenhauser C, Bychkov A, Klussmann JP, Quaas A, Buettner R, Tolkach Y. An agentic framework for autonomous scientific discovery in cancer pathology. Nat Med. 2026 Jun;32(6):2254-2266. doi: 10.1038/s41591-026-04357-y. Epub 2026 Apr 29. PMID: 42056496; PMCID: PMC13278948.
Tennigkeit J, Wiegelmann M, Massa C, Lübcke J, Dammermann W, Börner K, Schröter F, Seliger B, Kleinert M, Ritter O, Sachse G. Plasma GDF15 concentration predicts early recurrence after atrial arrhythmia ablation. JCI Insight. 2026 Feb 24;11(7):e198444. doi: 10.1172/jci.insight.198444. PMID: 41734019; PMCID: PMC13134712.
Udinotti M, Siebolts U, Bauer M, Vaxevanis C, Asiminas A, Lorenz K, Dierks C, Wickenhauser C, Seliger B. Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGFβ axis and immune suppression in aggressive thyroid cancer. J Transl Med. 2025 Nov 13;23(1):1284. doi: 10.1186/s12967-025-07307-3. PMID: 41233863; PMCID: PMC12616960.
Petroni G, Galassi C, Gouin KH 3rd, Chen HH, Buqué A, Bloy N, Yamazaki T, Sato A, Beltrán-Visiedo M, Campia G, Jiménez-Cortegana C, Shah A, Kirchmair A, Massa C, Wickenhauser C, de Andrea CE, Navarro-Rubio B, Serrano-Mendioroz I, Navarro Manzano E, Satty AM, Rippon B, Finotello F, Trajanoski Z, Zhou XK, Scandura JM, García-Martínez E, Ayala de la Peña F, Rodríguez-Ruiz ME, Seliger B, Sánchez-Margalet V, de la Cruz-Merino L, Basho RK, Shiao SL, McArthur HL, Formenti SC, Knott SRV, Galluzzi L. Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages. Nat Cancer. 2025 Oct;6(10):1754. doi: 10.1038/s43018-025-01036-8. Erratum for: Nat Cancer. 2025 Oct;6(10):1656-1675. doi: 10.1038/s43018-025-01007-z. PMID: 40702362.
Bauer M, Wilfer A, Zöllig C, Wickenhauser C, Seliger B. Multiparametric staining - combined application of immunofluorescence and in-situ hybridization. Methods Cell Biol. 2026;201:155-168. doi: 10.1016/bs.mcb.2025.09.001. Epub 2025 Sep 30. PMID: 41620274.
Vaxevanis C, Udinotti M, Kokoretsis D, Wilfer A, Bauer M, Wickenhauser C, Seliger B. Hema-CRISPR: A clone-based protocol for effective genetic editing of hematopoietic stem cells. Methods Cell Biol. 2026;201:185-194. doi: 10.1016/bs.mcb.2025.09.002. Epub 2025 Sep 29. PMID: 41620276.
Udinotti M, Siebolts U, Vaxevanis C, Seliger B. Extracellular matrix and morphology assessment method on live 3D spheroids of thyroid carcinoma. Methods Cell Biol. 2026;201:169-184. doi: 10.1016/bs.mcb.2025.09.011. Epub 2025 Sep 27. PMID: 41620275.
Heichel J, Burghardt ME, Struck HG, Paulsen F, Ali MJ, Viestenz A, Wickenhauser C, Dießel L. Histological Characteristics of Patients with Chronic Dacryocystitis, Depending on the Presence of Advanced Dacryolithiasis. Klin Monbl Augenheilkd. 2025 Dec;242(12):1178-1184. English, German. doi: 10.1055/a-2635-2419. Epub 2025 Sep 1. PMID: 40889753
Anh DD, The NT, Song LH, Mueller A, Velavan TP, Seliger B. Elevated Soluble HLA-G Levels Associate With Dengue Severity in Vietnamese Patients. J Med Virol. 2025 Sep;97(9):e70594. doi: 10.1002/jmv.70594. PMID: 40910405; PMCID: PMC12412082.
Bauer M, Vaxevanis C, Jaekel N, Hackl H, Wilfer A, Zoellig C, Haemmerle M, Müller-Tidow C, Al-Ali HK, Seliger B, Wickenhauser C. Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations. Leukemia. 2025 Oct;39(10):2391-2405. doi: 10.1038/s41375-025-02706-3. Epub 2025 Aug 5. PMID: 40764668; PMCID: PMC12463677.
Tong L, Tay AHM, Cui W, Liu Y, Su Y, Lyu J, Hoedemakers L, Yang Y, Ehnman M, Seliger B, Nordlund P, Haglund de Flon F, Neo SY, Lundqvist A. VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function. Cancer Immunol Immunother. 2025 Jul 30;74(9):278. doi: 10.1007/s00262-025-04132-x. PMID: 40736709; PMCID: PMC12311085.
Seliger B, Massa C. CyTOF as a suitable tool for stratification and monitoring of cancer patients. J Transl Med. 2025 Jul 1;23(1):724. doi: 10.1186/s12967-025-06764-0. PMID: 40598271; PMCID: PMC12220477.
Köhne M, Shakiba MH, Schmidleithner L, Schulte-Schrepping J, Scholz R, Elmzzahi T, Sommer D, Li Y, Carraro C, De Domenico E, Wißfeld J, Händler K, Hamada D, Frolov A, Cheng X, Baumgart AK, Holsten L, Osei-Sarpong C, Bourry S, Thabet Y, Renken H, Paulusch S, Sadlon T, Buch T, Wunderlich FT, Wickenhauser C, Alferink J, Kuhlmann T, Geyer M, Bonaguro L, Barry SC, Schultze JL, Beyer MD. Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. Cell Rep. 2025 Jul 22;44(7):115866. doi: 10.1016/j.celrep.2025.115866. Epub 2025 Jun 17. PMID: 40531625.
Bauer M, Santos P, Wilfer A, van den Berg E, Zietsman A, Vetter M, Kaufhold S, Wickenhauser C, Dos-Santos-Silva I, Chen WC, Cubasch H, Murugan N, McCormack V, Joffe M, Seliger B, Kantelhardt E. HIV status alters immune cell infiltration and activation profile in women with breast cancer. Nat Commun. 2025 May 20;16(1):4699. doi: 10.1038/s41467-025-59408-8. PMID: 40393975; PMCID: PMC12092689.
Horbas H, Bauer M, Eckert A, Bethmann D, Wilfer A, Seliger B, Wickenhauser C. Comparison of Manual Versus QuPath Software-based Immunohistochemical Scoring Using Oral Squamous Cell Carcinoma as a Model. J Histochem Cytochem. 2025 May-Jun;73(5-6):181-196. doi: 10.1369/00221554251335698. Epub 2025 May 15. PMID: 40371713; PMCID: PMC12081382.
Schreder K, Wickenhauser C, Kappler M, Tavassol F, Eckert AW. Metabolic biomarker in oral squamous cell carcinoma - a comprehensive review. GMS Interdiscip Plast Reconstr Surg DGPW. 2025 Apr 16;14:Doc01. doi: 10.3205/iprs000190. PMID: 40535577; PMCID: PMC12171862.
Barroso VM, Weng Z, Glamann L, Bauer M, Wickenhauser C, Zander T, Büttner R, Quaas A, Tolkach Y. Artificial Intelligence-Based Single-Cell Analysis as a Next-Generation Histologic Grading Approach in Colorectal Cancer: Prognostic Role and Tumor Biology Assessment. Mod Pathol. 2025 Jul;38(7):100771. doi: 10.1016/j.modpat.2025.100771. Epub 2025 Apr 11. PMID: 40222652.
Brandt A, Klinghammer K, Schultheiss C, Paschold L, Wickenhauser C, Bauer M, Bergqvist A, Hahn D, Schafhausen P, Tometten M, Blaurock M, Zech HB, Busch CJ, Dietz A, Müller-Richter U, Alt J, Boehm A, Kowoll S, Steighardt J, Lasch A, Westgaard IH, Westhrin M, Stein A, Hinke A, Binder M. UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial. Med. 2025 Jul 11;6(7):100647. doi: 10.1016/j.medj.2025.100647. Epub 2025 Apr 11. PMID: 40220758.
Di Giacomo AM, Subudhi S, Vos W, Andreatta M, Carmona S, McTavish W, Seliger B, Ibrahim R, Lahn M, Smith M, Eggermont A, Fox BA, Maio M. Perspectives on the role of "-Omics" in predicting response to immunotherapy. Eur J Cancer. 2025 May 2;220:115393. doi: 10.1016/j.ejca.2025.115393. Epub 2025 Mar 30. PMID: 40168935.
Tong L, Kremer V, Neo SY, Seitz C, Tobin NP, Seliger B, Harmenberg U, Colón E, Scherman Plogell AH, Liu LL, Lundqvist A. Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients. Oncoimmunology. 2025 Dec;14(1):2481109. doi: 10.1080/2162402X.2025.2481109. Epub 2025 Mar 24. PMID: 40126183; PMCID: PMC11934188.
Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM, Cillo AR, Collyar D, Cope L, Deutsch JS, Dubrovsky G, Gnjatic S, Goh D, Halabi S, Kohanbash G, Maecker HT, Maleki Vareki S, Mullin S, Seliger B, Taube J, Vos W, Yeong J, Anderson KG, Bruno TC, Chiuzan C, Diaz-Padilla I, Garrett-Mayer E, Glitza Oliva IC, Grandi P, Hill EG, Hobbs BP, Najjar YG, Pettit Nassi P, Simons VH, Subudhi SK, Sullivan RJ, Takimoto CH. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer. 2025 Mar 7;13(3):e010928. doi: 10.1136/jitc-2024-010928. PMID: 40054999; PMCID: PMC11891540.
Subbarayan K, Bieber H, Massa C, Rodríguez FAE, Hossain SMAA, Neuder L, Wahbi W, Salo T, Tretbar S, Al-Samadi A, Seliger B. Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers. J Transl Med. 2025 Mar 7;23(1):294. doi: 10.1186/s12967-025-06177-z. PMID: 40055791; PMCID: PMC11887338.
Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich TJ, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Bokemeyer C, Sinn M, Lindig U, Hinke A, Hegewisch-Becker S, Stein A, Binder M. Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy. Cancer Immunol Res. 2025 Feb 3;13(2):200-209. doi: 10.1158/2326-6066.CIR-24-0561. PMID: 39527097; PMCID: PMC11788649.
Willscher E, Schultheiß C, Paschold L, Lea Schümann F, Schmidt-Barbo P, Thiele B, Bauer M, Wickenhauser C, Weber T, Binder M. T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas. Haematologica. 2025 Feb 1;110(2):457-469. doi: 10.3324/haematol.2024.285395. PMID: 39219501; PMCID: PMC11788643
Escalona-Rodriguez FA, La O-Bonet J, Tasies LPF, Subbarayan K, Rivero-Hernández AL, Sifontes-Niebla M, Manso-Vargas A, De Cola L, Ventosa N, Sánchez B, Alvarez C, G Rivera D, Seliger B, Lanio ME. Development of a StIW111C-based bioresponsive pore-forming conjugate for permeabilizing the endosomal membrane. Int J Biol Macromol. 2025 Mar;297:139819. doi: 10.1016/j.ijbiomac.2025.139819. Epub 2025 Jan 13. PMID: 39814294.
Mantke R, Seliger B, Ogino S, Büchler MW, Hunger R. Not Only Caseload but Also Patient Selection Is Predictive of Mortality After Pancreatic Resection. Ann Surg Open. 2024 Dec 30;6(1):e536. doi: 10.1097/AS9.0000000000000536. PMID: 40134472; PMCID: PMC11932614.
Weng Z, Seper A, Pryalukhin A, Mairinger F, Wickenhauser C, Bauer M, Glamann L, Bläker H, Lingscheidt T, Hulla W, Jonigk D, Schallenberg S, Bychkov A, Fukuoka J, Braun M, Schömig-Markiefka B, Klein S, Thiel A, Bozek K, Netto GJ, Quaas A, Büttner R, Tolkach Y. GrandQC: A comprehensive solution to quality control problem in digital pathology. Nat Commun. 2024 Dec 16;15(1):10685. doi: 10.1038/s41467-024-54769-y. PMID: 39681557; PMCID: PMC11649692.
Subbarayan K, Al-Samadi A, Schäfer H, Massa C, Salo T, Biehl K, Vaxevanis CK, Ulagappan K, Wahbi W, Reimers M, Drexler F, Moreira-Soto A, Bachmann M, Seliger B. Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors. Cell Mol Life Sci. 2024 Dec 3;81(1):473. doi: 10.1007/s00018-024-05520-9. PMID: 39625479; PMCID: PMC11615173.
Yohannes M, Massa C, Desalegn Z, Stückrath K, Mueller A, Anberber E, Bekuretsion Y, Assefa M, Santos P, Addissie A, Bauer M, Wickenhauser C, Taylor L, Vetter M, Kantelhardt EJ, Abebe T, Seliger B. Blood immune profiling of Ethiopian patients with breast cancer highlights different forms of immune escape. Oncoimmunology. 2024 Dec 31;13(1):2436227. doi: 10.1080/2162402X.2024.2436227. Epub 2024 Dec 2. PMID: 39621040; PMCID: PMC11622621.
Lutz R, Grünschläger F, Simon M, Awwad MHS, Bauer M, Yousefian S, Beumer N, Jopp-Saile L, Sedlmeier A, Solé-Boldo L, Avanesyan B, Vonficht D, Stelmach P, Steinbuss G, Boch T, Steiger S, Baertsch MA, Prokoph N, Rippe K, Durie BGM, Wickenhauser C, Trumpp A, Müller-Tidow C, Hübschmann D, Weinhold N, Raab MS, Brors B, Goldschmidt H, Imbusch CD, Hundemer M, Haas S. Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy. Nat Commun. 2024 Nov 29;15(1):10396. doi: 10.1038/s41467-024-54543-0. PMID: 39613747; PMCID: PMC11607340.
Yohannes M, Desalegn Z, Bauer M, Stückrath K, Anberbir E, Bekuretsion Y, Assefa M, Wakuma T, Worku Y, Santos PSC, Taylor L, Adissie A, Wickenhauser C, Massa C, Vetter M, Kantelhardt EJ, Seliger B, Abebe T. Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients. Breast Cancer Res. 2024 Nov 25;26(1):162. doi: 10.1186/s13058-024-01916-4. PMID: 39587630; PMCID: PMC11587711.
Saleem SK, Decker S, Kissel S, Bauer M, Chernyakov D, Bräuer-Hartmann D, Aumann K, Wickenhauser C, Herling M, Skorobohatko O, Mathew N, Schmidt C, Klein C, Follo M, Dierks C. JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. J Exp Med. 2025 Jan 6;222(1):e20230681. doi: 10.1084/jem.20230681. Epub 2024 Nov 21. PMID: 39570282; PMCID: PMC11586660.
Seliger B. "Tumor immunology meets oncology" (TIMO), 18 April-20 April 2024, in Brandenburg an der Havel, Germany. Cancer Immunol Immunother. 2024 Nov 13;74(1):19. doi: 10.1007/s00262-024-03877-1. PMID: 39535567; PMCID: PMC11561215.
Branz A, Matek C, Lange F, Bahlinger V, Klümper N, Hölzel M, Strissel PL, Strick R, Sikic D, Wach S, Taubert H, Wullich B, Hartmann A, Seliger B, Eckstein M. HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance. Front Immunol. 2024 Oct 14;15:1478196. doi: 10.3389/fimmu.2024.1478196. PMID: 39469714; PMCID: PMC11513269.
Wang Y, Lazaridou MF, Kordaß T, Massa C, Vaxevanis CK, Eichmüller S, Seliger B. Unconventional microRNA role: Enhancing the human leukocyte antigen class I antigen processing pathway via interacting with a silencer. Clin Transl Med. 2024 Oct;14(10):e70010. doi: 10.1002/ctm2.70010. PMID: 39439221; PMCID: PMC11496566.
Ballé JK, Vetter M, Kenea TW, Eber-Schulz P, Reibold C, Ziegenhorn HV, Stückrath K, Wickenhauser C, Addissie A, Santos P, Kantelhardt EJ, Getachew S, Bauer M. PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study. BMC Cancer. 2024 Sep 10;24(1):1127. doi: 10.1186/s12885-024-12867-6. PMID: 39256703; PMCID: PMC11385137.
Ohlinger J, Vordermark D, Ostheimer C, Bache M, Tzschoppe T, Demircan K, Schomburg L, Medenwald D, Seliger B. Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival. Strahlenther Onkol. 2025 Jun;201(6):616-626. doi: 10.1007/s00066-024-02276-w. Epub 2024 Sep 6. PMID: 39240366; PMCID: PMC12119749.
Vaxevanis C, Bachmann M, Seliger B. Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy. J Immunother Cancer. 2024 Aug 29;12(8):e009774. doi: 10.1136/jitc-2024-009774. PMID: 39209767; PMCID: PMC11367391.
Bauer M, Monecke A, Hackl H, Wilfer A, Jaekel N, Bläker H, Al-Ali HK, Seliger B, Wickenhauser C. Association of immune evasion in myeloid sarcomas with disease manifestation and patients' survival. Front Immunol. 2024 Aug 7;15:1396187. doi: 10.3389/fimmu.2024.1396187. PMID: 39170623; PMCID: PMC11336574.
Stein M, Hämmerle M, Viestenz A, Wickenhauser C, Glien A, Struck HG, Heichel J. Pleomorphes Adenom aus ektopem Tränendrüsengewebe – Management eines großen extrakonalen retroäquatorialen Tumors über eine anteriore transkutane Orbitotomie [Pleomorphic adenoma of ectopic lacrimal gland tissue – management of a large extraconal retroaquaetorial tumor via anterior transcutaneous orbitotomy]. Laryngorhinootologie. 2025 Apr;104(4):250-254. German. doi: 10.1055/a-2341-1100. Epub 2024 Jul 29. PMID: 39074804.
Wang Y, Seliger B. Identification of RNA-binding protein hnRNP C targeting the 3'UTR of the TAP-associated glycoprotein tapasin in melanoma. Oncoimmunology. 2024 Jun 27;13(1):2370928. doi: 10.1080/2162402X.2024.2370928. PMID: 38948930; PMCID: PMC11212565.
Machens A, Lorenz K, Bensch C, Wickenhauser C, Dralle H. Tumor desmoplasia outperforms preoperative serum calcitonin as surgical biomarker in sporadic medullary thyroid cancer. Head Neck. 2024 Nov;46(11):2843-2852. doi: 10.1002/hed.27827. Epub 2024 Jun 8. PMID: 38850101.
Bauer M, Schöbel CM, Wickenhauser C, Seliger B, Jasinski-Bergner S. Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies. Front Immunol. 2024 Apr 26;15:1386993. doi: 10.3389/fimmu.2024.1386993. PMID: 38736877; PMCID: PMC11082354.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Uwe Blohmer J, Zahm DM, Jackisch C, Mackelenbergh MV, Thomalla J, Marmé F, Huober J, Müller V, Schem C, Müller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clin Transl Med. 2024 Apr;14(4):e1617. doi: 10.1002/ctm2.1617. PMID: 38664548; PMCID: PMC11045558.
Seliger B. Role of HLA-G in tumors and upon COVID-19 infection. Hum Immunol. 2024 May;85(3):110792. doi: 10.1016/j.humimm.2024.110792. Epub 2024 Mar 29. PMID: 38555250.
Bauer M, Jäkel N, Wilfer A, Haak A, Eszlinger M, Kelemen K, Haemmerle M, Al-Ali HK, Seliger B, Wickenhauser C. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML. Oncoimmunology. 2024 Mar 6;13(1):2323212. doi: 10.1080/2162402X.2024.2323212. PMID: 38481730; PMCID: PMC10936680.
Hassan L, Bedir A, Kraus FB, Ostheimer C, Vordermark D, Mikolajczyk R, Seliger B, Medenwald D. Correlation of Increased Soluble Tumor Necrosis Factor Receptor 1 with Mortality and Dependence on Treatment in Non-Small-Cell Lung Cancer Patients: A Longitudinal Cohort Study. Cancers (Basel). 2024 Jan 26;16(3):525. doi: 10.3390/cancers16030525. PMID: 38339276; PMCID: PMC10854918.
Machens A, Bensch C, Wickenhauser C, Dralle H, Lorenz K. Comparing nodal with primary tumor desmoplasia uncovers metastatic patterns in multiple endocrine neoplasia 2B. Eur J Endocrinol. 2024 Jan 3;190(1):K21-K25. doi: 10.1093/ejendo/lvad177. PMID: 38147465.